Inebilizumab is a medicine used to treat neuromyelitis optica spectrum disorder (NMOSD), IgG4-related disease, and generalized myasthenia gravis. It is given as an infusion into a vein. It works by removing certain immune cells that make the antibodies that attack the body.
Every report comes from a Lived member, sent anonymously.
Have you tried Uplizna (Inebilizumab) for Neuromyelitis Optica?
Inebilizumab, sold as Uplizna, is a prescription antibody medicine given by infusion into a vein. It is used to calm three autoimmune diseases, conditions in which the immune system makes antibodies that attack the body's own tissues. It is approved for adults only. Its first approved use is neuromyelitis optica spectrum disorder (NMOSD), a rare disease in which the immune system attacks the optic nerves and spinal cord, causing attacks of vision loss, weakness or numbness that can leave lasting disability. Uplizna is for people whose blood test shows antibodies to aquaporin-4 (AQP4), a protein on cells in the brain and spinal cord; in its main trial it did not show benefit for people without these antibodies. Its purpose is to prevent future attacks rather than to treat one already underway. It is also approved for IgG4-related disease, a condition in which immune cells build up in organs such as the pancreas, bile ducts, salivary glands or kidneys, causing swelling and, over time, scarring. Here it is used to prevent flares and reduce reliance on steroid medicines. The third use is generalized myasthenia gravis, an autoimmune disease that causes muscle weakness that worsens with use, in adults whose antibodies target the acetylcholine receptor (AChR) or a protein called MuSK, two parts of the junction where nerves signal muscles.
In all three diseases, a type of white blood cell called the B cell plays a central role. B cells and the cells they mature into produce antibodies, including the harmful antibodies that drive NMOSD and myasthenia gravis, and they help sustain the inflammation in IgG4-related disease. Inebilizumab is a lab-made antibody that attaches to CD19, a marker found on B cells from an early stage of their development through to many antibody-producing cells. Once attached, it flags those cells for destruction by the immune system. B-cell counts in the blood drop within days to weeks of the first infusion and stay low between doses, which is why infusions are spaced six months apart. Lowering B cells reduces the immune activity behind attacks and flares, but it also weakens part of the body's normal defense against infection.
Uplizna is given in an infusion center or clinic. Treatment starts with two infusions two weeks apart, followed by one infusion every 6 months. The dose is the same for all three conditions. Each infusion takes about 90 minutes, starting slowly and speeding up if it is well tolerated, and staff watch for reactions during the infusion and for at least an hour afterward. About 30 to 60 minutes beforehand, people receive premedication: a steroid through the vein, an antihistamine and a fever reducer such as acetaminophen, to lower the chance of an infusion reaction. Before every infusion the team checks for an active infection, and the dose is postponed until any infection clears. Before the first dose, blood tests check for hepatitis B, for tuberculosis (TB) and for baseline antibody (immunoglobulin) levels. Any needed vaccines are ideally given at least 4 weeks before starting.
The most common side effects in clinical trials were urinary tract infections, colds and other upper respiratory infections, joint pain, back pain and headache. Blood tests may show lower counts of lymphocytes, a type of white blood cell, which is an expected result of how the drug works. Infusion reactions affected roughly 1 in 10 people in the trials, most often during the first infusion. They can cause headache, nausea, sleepiness, rash, fever, muscle aches, a racing heartbeat or shortness of breath, and in rare cases a severe allergic reaction (anaphylaxis). Because infusions are supervised, staff can slow or stop the drip and treat symptoms. Symptoms that appear after you leave should be reported to the care team right away. Because Uplizna lowers B cells, infections are more likely and can occasionally be serious or life-threatening, during treatment and for some time after the last dose. Contact the care team if you develop fever, chills, a cough that won't go away, or pain or burning when urinating.
Uplizna is not given to people with active hepatitis B, active TB or TB infection that has not been treated, or anyone who has had a life-threatening reaction to a previous Uplizna infusion. In people who have had hepatitis B in the past, the virus can reactivate and cause severe liver damage, so a liver specialist is usually involved and monitoring continues during treatment. Progressive multifocal leukoencephalopathy (PML) is a rare, often disabling or fatal brain infection that has occurred with similar B-cell-lowering medicines, although no confirmed cases were seen in Uplizna trials. Its symptoms build over days to weeks: weakness on one side of the body, clumsiness, changes in vision, or new confusion or memory and personality changes. Report these to the care team promptly. Taking Uplizna with other medicines that suppress the immune system, including steroid pills such as prednisone, can raise infection risk further, so the team weighs these combinations. Live vaccines, which contain a weakened form of the germ, are not recommended during treatment or until B cells recover after stopping. Uplizna crosses the placenta and may harm a developing baby's immune system. People who could become pregnant are advised to use effective contraception during treatment and for at least 6 months after the last dose, and to tell the prescriber about pregnancy or plans for it. A baby exposed in the womb should not receive live vaccines until the baby's B cells are confirmed to have recovered. Whether the drug passes into breast milk is not known.
Uplizna works by preventing future attacks or flares rather than reversing damage already done, so its benefit shows up as fewer relapses over months and years. In the NMOSD trial, about 11 percent of people on Uplizna had an attack over roughly six and a half months, compared with about 42 percent on placebo, and fewer needed hospital care. In IgG4-related disease, about 10 percent flared over a year versus 60 percent on placebo, and more than half stayed in remission without further steroid treatment. In myasthenia gravis, people on Uplizna improved by about 2 more points than those on placebo on a 0 to 24 daily-activities scale where higher scores mean more weakness; individual responses varied. For most people, Uplizna is a long-term treatment. Between infusions, the care team typically follows symptoms, blood counts and immunoglobulin levels, because antibody levels can drift downward over time. If levels fall low and infections become frequent or serious, the team may reconsider continuing. After stopping, B cells take months to recover, so infection precautions and the live-vaccine restriction last beyond the final dose.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Uplizna (Inebilizumab), what you've noticed, or ask the community a question.